Navigation Links
Velos, Inc. Releases Software to Support Cancer Centers With New Workflow and Content for NCI Clinical Trials Reporting Program
Date:7/16/2009

ntees will enter specific information about each clinical trial into the database. NCI will use this information to coordinate research efforts to optimize our nation's investment in cancer research. NCI initiated a phased launch of CTRP, which started in 2009 with a focus on registering interventional trials only. For more information, visit http://www.cancer.gov/clinicaltrials/ctrp.

About Velos

Velos is the trusted clinical trial management resource for investigators, sponsors and academic leaders throughout the U.S. The company serves 21 Top 25* U.S. medical centers. Velos eResearch is deployed for clinical research in all parts of the healthcare enterprise and supports a broad diversity of clinical departments and functional needs. The system fundamentally improves the way data is collected, organized and shared. A pure Internet technology platform, Velos eResearch harnesses advanced powers of the Internet to enable research sites, sponsors, and patients to participate in a secure, integrated system platform. System users are freed of redundant data entry and related time delays associated with most clinical research today. With emphasis on workflow, Velos integrates the clinical, administrative and financial information needs of research management. Velos eTools, a companion product to Velos eResearch, empowers customers by giving them ownership and access to functions such as system configuration, data migrations, custom reporting and third party data submissions. Velos is privately held with headquarters in Fremont, California. For more information, visit www.velos.com.

This press release may contain forward-looking statements that are subject to risks and uncertainties
'/>"/>

SOURCE Velos, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Sarasotas Roskamp Institute Releases Study Defining a Mechanism for Development of Obesity and the Metabolic Syndrome, Forerunners of Type 2 Diabetes
2. CEL-SCI Corporation Releases Letter to Shareholders
3. AcroMetrix Releases New OptiQuant(R) HIV-1 Quantification Panel
4. Cardinal Health Releases New Tool to Combat MRSA Infections in Hospitals
5. Immunosyn Corporation Releases SF-1019 Study Results
6. TCS Healthcare Technologies Releases Three New Clinical Care Programs Within ACUITY
7. Immunosyn Releases Wound Healing Photographs From the First Phase Proof of Concept Trial in Europe for Treatment of Diabetic Ulcers With Biopharmeceutical SF-1019
8. QRxPharma Releases Successful Phase 3 Study Results for Dual Opioid Pain Therapy
9. CenterWatch Releases State of the Clinical Trials Industry 2008 - A Key Industry Resource for Market Research and Competitive Intelligence
10. QRxPharma Releases Additional Phase 3 Data for Q8003IR Dual Opioid Pain Therapy
11. Genaera Releases Phase 1 Data and New Preclinical Data on the CNS Function of Trodusquemine (MSI-1436) at CBI Obesity Summit
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/15/2009)... Medical, Inc. (Nasdaq: NXTM ), a leading ... a group of its home hemodialysis patients and ... conventional (non-dialysis) Caribbean cruise with their NxStage® System ... Freedom Cruise: We,re Taking Home Dialysis to Sea," ... and returns on January 10, 2010. The ...
(Date:12/15/2009)... Today, Hill-Rom Holdings, Inc. (NYSE: ... on significant strategic and financial initiatives at its ... Conference is hosted by Peter H. Soderberg, president ... on the following topics: ,, Status of ... development and financial updates Smart technologies that ...
(Date:12/15/2009)... Inc., a family-owned Texas company that produces the ... a patented medical device being utilized by U.S. ... to lessen the effects of fluid-induced hypothermia ... Tahoe as the first-ever recipient of their "Thermal Angel ... is a California-based nonprofit emergency helicopter service headquartered in ...
Breaking Medicine Technology:Group of NxStage(R) Home Hemodialysis Patients to Take Caribbean Cruise with the System One(TM) 2Group of NxStage(R) Home Hemodialysis Patients to Take Caribbean Cruise with the System One(TM) 3Group of NxStage(R) Home Hemodialysis Patients to Take Caribbean Cruise with the System One(TM) 4Hill-Rom Investor Conference Features Business Strategy Updates and New Technologies 2Hill-Rom Investor Conference Features Business Strategy Updates and New Technologies 3Hill-Rom Investor Conference Features Business Strategy Updates and New Technologies 4Hill-Rom Investor Conference Features Business Strategy Updates and New Technologies 5Hill-Rom Investor Conference Features Business Strategy Updates and New Technologies 6Hill-Rom Investor Conference Features Business Strategy Updates and New Technologies 7Thermal Angel Blood Warmer Recognizes CALSTAR 6 With Distinguished Emergency Responder Award 2Thermal Angel Blood Warmer Recognizes CALSTAR 6 With Distinguished Emergency Responder Award 3Thermal Angel Blood Warmer Recognizes CALSTAR 6 With Distinguished Emergency Responder Award 4Ethics and Healthcare Reform Panel Community Forum Open to Public November 17 60593 1Ethics and Healthcare Reform Panel Community Forum Open to Public November 17 60593 2Ethics and Healthcare Reform Panel Community Forum Open to Public November 17 60593 3Cardiac Science to Present at Third Annual Canaccord Adams Cardiovascular Conference 5947 1Cardiac Science to Present at Third Annual Canaccord Adams Cardiovascular Conference 5947 2Cardiac Science to Present at Third Annual Canaccord Adams Cardiovascular Conference 5947 3Cardiac Science to Present at Third Annual Canaccord Adams Cardiovascular Conference 5947 4Medco Delivers Record Third Quarter 2009 GAAP Diluted EPS of 240 69 3B Diluted EPS Excluding Amortization of Intangible Assets of 240 75 5944 1Medco Delivers Record Third Quarter 2009 GAAP Diluted EPS of 240 69 3B Diluted EPS Excluding Amortization of Intangible Assets of 240 75 5944 2Medco Delivers Record Third Quarter 2009 GAAP Diluted EPS of 240 69 3B Diluted EPS Excluding Amortization of Intangible Assets of 240 75 5944 3Medco Delivers Record Third Quarter 2009 GAAP Diluted EPS of 240 69 3B Diluted EPS Excluding Amortization of Intangible Assets of 240 75 5944 4Medco Delivers Record Third Quarter 2009 GAAP Diluted EPS of 240 69 3B Diluted EPS Excluding Amortization of Intangible Assets of 240 75 5944 5Medco Delivers Record Third Quarter 2009 GAAP Diluted EPS of 240 69 3B Diluted EPS Excluding Amortization of Intangible Assets of 240 75 5944 6Medco Delivers Record Third Quarter 2009 GAAP Diluted EPS of 240 69 3B Diluted EPS Excluding Amortization of Intangible Assets of 240 75 5944 7Medco Delivers Record Third Quarter 2009 GAAP Diluted EPS of 240 69 3B Diluted EPS Excluding Amortization of Intangible Assets of 240 75 5944 8Medco Delivers Record Third Quarter 2009 GAAP Diluted EPS of 240 69 3B Diluted EPS Excluding Amortization of Intangible Assets of 240 75 5944 9Medco Delivers Record Third Quarter 2009 GAAP Diluted EPS of 240 69 3B Diluted EPS Excluding Amortization of Intangible Assets of 240 75 5944 10Medco Delivers Record Third Quarter 2009 GAAP Diluted EPS of 240 69 3B Diluted EPS Excluding Amortization of Intangible Assets of 240 75 5944 11Medco Delivers Record Third Quarter 2009 GAAP Diluted EPS of 240 69 3B Diluted EPS Excluding Amortization of Intangible Assets of 240 75 5944 12Medco Delivers Record Third Quarter 2009 GAAP Diluted EPS of 240 69 3B Diluted EPS Excluding Amortization of Intangible Assets of 240 75 5944 13Medco Delivers Record Third Quarter 2009 GAAP Diluted EPS of 240 69 3B Diluted EPS Excluding Amortization of Intangible Assets of 240 75 5944 14Medco Delivers Record Third Quarter 2009 GAAP Diluted EPS of 240 69 3B Diluted EPS Excluding Amortization of Intangible Assets of 240 75 5944 15Medco Delivers Record Third Quarter 2009 GAAP Diluted EPS of 240 69 3B Diluted EPS Excluding Amortization of Intangible Assets of 240 75 5944 16Medco Delivers Record Third Quarter 2009 GAAP Diluted EPS of 240 69 3B Diluted EPS Excluding Amortization of Intangible Assets of 240 75 5944 17Medco Delivers Record Third Quarter 2009 GAAP Diluted EPS of 240 69 3B Diluted EPS Excluding Amortization of Intangible Assets of 240 75 5944 18Medco Delivers Record Third Quarter 2009 GAAP Diluted EPS of 240 69 3B Diluted EPS Excluding Amortization of Intangible Assets of 240 75 5944 19Medco Delivers Record Third Quarter 2009 GAAP Diluted EPS of 240 69 3B Diluted EPS Excluding Amortization of Intangible Assets of 240 75 5944 20Medco Delivers Record Third Quarter 2009 GAAP Diluted EPS of 240 69 3B Diluted EPS Excluding Amortization of Intangible Assets of 240 75 5944 21Medco Delivers Record Third Quarter 2009 GAAP Diluted EPS of 240 69 3B Diluted EPS Excluding Amortization of Intangible Assets of 240 75 5944 22Medco Delivers Record Third Quarter 2009 GAAP Diluted EPS of 240 69 3B Diluted EPS Excluding Amortization of Intangible Assets of 240 75 5944 23Medco Delivers Record Third Quarter 2009 GAAP Diluted EPS of 240 69 3B Diluted EPS Excluding Amortization of Intangible Assets of 240 75 5944 24Medco Delivers Record Third Quarter 2009 GAAP Diluted EPS of 240 69 3B Diluted EPS Excluding Amortization of Intangible Assets of 240 75 5944 25Medco Delivers Record Third Quarter 2009 GAAP Diluted EPS of 240 69 3B Diluted EPS Excluding Amortization of Intangible Assets of 240 75 5944 26Medco Delivers Record Third Quarter 2009 GAAP Diluted EPS of 240 69 3B Diluted EPS Excluding Amortization of Intangible Assets of 240 75 5944 27Medco Delivers Record Third Quarter 2009 GAAP Diluted EPS of 240 69 3B Diluted EPS Excluding Amortization of Intangible Assets of 240 75 5944 28Medco Delivers Record Third Quarter 2009 GAAP Diluted EPS of 240 69 3B Diluted EPS Excluding Amortization of Intangible Assets of 240 75 5944 29
(Date:12/15/2009)... say that phthalates actually cause the condition, ... -- Common chemicals found in plastic toys and ... breasts in boys, preliminary research suggests. , ... for pediatricians, adds fuel to the debate over ... questioned by some scientists. The chemical industry claims ...
(Date:12/15/2009)... benefits of imaging outweigh the risks , , TUESDAY, Dec. ... serious risk to people with heart pacemakers, researchers warn. ... to a simulated MRI magnetic field and then measured ... pacemaker lead, where it would touch the interior of ... pulses caused certain pacemakers to deliver a drastically altered ...
(Date:12/15/2009)... -- Accelify is proud to announce the addition of ... will serve as Director of Development in the State ... of Advisors. ,, David Tokofsky was elected ... Education in June 1995. As the Board Member for ... stretching from Northeast Los Angeles through East Los Angeles ...
(Date:12/15/2009)... SMITHFIELD, R.I., Dec. 15 Mergers and ... to expand their reach globally or complete a ... including the integration of safety programs. ,, A ... " Best Practices in a Hearing Conservation Program: ... US Airways and America West led the newly ...
(Date:12/15/2009)... YORK, Dec. 15 Reportlinker.com ... report is available in its catalogue: ... Autoimmune Diseases Therapeutics - Market Forecasts ... and Deals Analysis ,, ... ,, The author has released ...
Breaking Medicine News(10 mins):Health News:Breast Growth in Boys Might Be Linked to Plastics Chemical 2Health News:Breast Growth in Boys Might Be Linked to Plastics Chemical 3Health News:Patients With Pacemakers Should Avoid MRI Scans 2Health News:Accelify Announces the Addition of David Tokofsky to its National Board of Advisors 2Health News:New White Paper Details Best Practices of an Occupational Hearing Conservation Program: US Airways 2Health News:New White Paper Details Best Practices of an Occupational Hearing Conservation Program: US Airways 3Health News:New White Paper Details Best Practices of an Occupational Hearing Conservation Program: US Airways 4Health News:Reportlinker Adds The Future of Autoimmune Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 2Health News:Reportlinker Adds The Future of Autoimmune Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 3Health News:Reportlinker Adds The Future of Autoimmune Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 4Health News:Reportlinker Adds The Future of Autoimmune Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 5Health News:Reportlinker Adds The Future of Autoimmune Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 6Health News:Reportlinker Adds The Future of Autoimmune Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 7Health News:Reportlinker Adds The Future of Autoimmune Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 8Health News:Reportlinker Adds The Future of Autoimmune Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 9Health News:Reportlinker Adds The Future of Autoimmune Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 10Health News:Reportlinker Adds The Future of Autoimmune Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 11Health News:Reportlinker Adds The Future of Autoimmune Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 12Health News:Reportlinker Adds The Future of Autoimmune Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 13Health News:Reportlinker Adds The Future of Autoimmune Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 14Health News:Reportlinker Adds The Future of Autoimmune Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 15Health News:Reportlinker Adds The Future of Autoimmune Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 16Health News:Reportlinker Adds The Future of Autoimmune Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 17Health News:Reportlinker Adds The Future of Autoimmune Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 18Health News:Reportlinker Adds The Future of Autoimmune Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 19Health News:Reportlinker Adds The Future of Autoimmune Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 20Health News:Reportlinker Adds The Future of Autoimmune Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 21Health News:Reportlinker Adds The Future of Autoimmune Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 22Health News:Reportlinker Adds The Future of Autoimmune Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 23
... of HDL level, study found , MONDAY, Aug. 27 (HealthDay ... do not protect against increased blood pressure in ... The study of more than 21,000 men, ages 20-29 and ... the younger men to blood pressure increases associated with heavy ...
... Using magnetic resonance (MR) images of the brain, researchers ... and disability in patients with multiple sclerosis (MS), according ... Radiology. , Based on these findings, physicians may ... identify patients at risk for developing progressive disease, said ...
... scientists have found the first evidence that a specific form ... increase the risk for estrogen-induced cancers of the breast and ... the animal equivalent of multiple sclerosis. , IMPACT: ... for anti-inflammatory drugs to help prevent flare-ups of their physical ...
... should be available an open question, researcher says , , ... from cardiac arrest while on school grounds, it makes the ... school property is rare, and most of the victims are ... medical service calls in the Seattle area, researchers found that ...
... reduce incidence, experts say, , , MONDAY, Aug. 27 (HealthDay News) ... be responsible for most cervical cancers, may also be at ... new research suggests. , Although the rate of most head ... years because more people have stopped smoking, the rate of ...
... more dangerous for women than men, major study finds , ... are at significantly increased risk for head and neck cancers ... oral cavity, and throat, says a U.S. National Cancer Institute ... men and women between 1995 and 2000. , The analysis ...
Other Medicine News:Health News:New MRI finding sheds light on multiple sclerosis disease progressio 2Health News:Heart Attacks at School Involve More Adults Than Kids 2Health News:Heart Attacks at School Involve More Adults Than Kids 3Health News:Oral Sex Implicated in Some Throat and Neck Cancers 2Health News:Oral Sex Implicated in Some Throat and Neck Cancers 3
Reliable and Affordable. The Schuco 3000 Nebulizer by Allied has been designed to offer a compact style that provides worry-free affordable nebulizer therapy....
... been developing diverse medical products ... Our medical-surgical products have earned ... quality and customer satisfaction. Graham-Fields ... Labtron® line of diagnostic instruments, ...
... Nebulizers deliver particulate humidity in the 3 ... secretion patients. For your convenience, Thera-Mist® nebulizers ... of sterile water., ,The P30000N, for ... 20-50% with a total flow range of ...
... Our Hand Held Nebulizer can be held ... It has a built in spill column, ... legs for medication setups and 7 feet of ... baffle plate maintain small particle size and sustain ...
Medicine Products: